Nitroxyl, or HNO, is a distinct chemical moiety whose biological and physiological effects are mediated by a reversible direct reaction with thiolates in selected target proteins. There is considerable evidence that nitroxyl is formed endogenously, and that it may represent a unique, previously un-appreciated signaling pathway.
While their chemical formulas are similar, nitroxyl (HNO) is chemically and biologically quite distinct from nitric oxide (NO); there is no significant chemical interconversion between the species under normal physiological conditions, and nitroxyl's molecular interactions in cardiovascular tissue are unique.
Cardioxyl's most advanced program is focused on the development of proprietary nitroxyl donors for the treatment of acute decompensated heart failure (ADHF). Programs targeting Chronic Heart Failure, and Pulmonary Arterial Hypertension, as well as other cardiovascular therapeutic indications, are also in preclinical development.
Other programs targeting additional cardiovascular therapeutic indications are in preclinical development.